Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price target reduced by Morgan Stanley from $61.00 to $59.00 in a research report report published on Tuesday, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently issued reports on HALO. Benchmark reiterated a buy rating […]
Linden Thomas Advisory Services LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 13.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 42,450 shares of the biopharmaceutical company’s stock after purchasing an additional 5,126 shares […]
StockNews.com upgraded shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) from a hold rating to a buy rating in a research report released on Monday morning. Other analysts also recently issued reports about the company. Benchmark reissued a buy rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a report on […]
Campbell Newman Asset Management Inc. cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 34,061 shares of the biopharmaceutical company’s stock after selling 595 shares during the quarter. Campbell Newman […]
WCM Investment Management LLC lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 23.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 292,232 shares of the biopharmaceutical company’s stock after acquiring an additional 55,864 shares during the quarter. WCM […]